Abraxis BioScience Appoints Rick Rodgers Chief Financial Officer

LOS ANGELES--(Business Wire)--
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical
company, today announced the appointment of Rick Rodgers as Senior Vice
President and Chief Financial Officer, succeeding David O`Toole.

"Rick is a dynamic executive who is well adept at leading organizations that are
experiencing rapid growth," said Lonnie Moulder, President and Chief Executive
Officer. "Having worked together in the recent past, I can attest to his broad
range of abilities and financial acumen and am confident he will be a valuable
asset to the Abraxis team. I would also like to acknowledge David`s many
contributions to the company and appreciate his guidance in effecting a smooth
transition."

Mr. Rodgers most recently was Senior Vice President, Controller and Chief
Accounting Officer of MGI Pharma until the company`s acquisition by Eisai
Corporation in 2008. In 2003, Mr. Rodgers was Corporate Controller of MedSource
Technologies and from 1997 to 2002, he held various senior positions at ADC
Telecommunications Inc. Prior to that, he held finance and accounting positions
at several private and public companies. Mr. Rodgers began his financial career
in accounting at Arthur Anderson & Co. Mr. Rodgers earned his bachelor of
science degree in Financial Accounting from St. Cloud State University, Minn.,
and his master of business administration degree in Finance from the University
of Minnesota, Carlson School of Business.

About Abraxis BioScience, Inc.

Abraxis BioScience is a fully integrated global biotechnology company dedicated
to the discovery, development and delivery of next-generation therapeutics and
core technologies that offer patients safer and more effective treatments for
cancer and other critical illnesses. The company's portfolio includes the
world's first and only protein-bound nanoparticle chemotherapeutic compound
(ABRAXANE®), which is based on the company's proprietary tumor targeting
technology known as the nab® platform. The first FDA approved product to use
this nab platform, ABRAXANE, was launched in 2005 for the treatment of
metastatic breast cancer and is now approved in 36 countries. The company
continues to expand the nab platform through a robust clinical program and deep
product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol
ABII. For more information about the company and its products, please visit
www.abraxisbio.com.

Investors and Media Inquiries:
Abraxis BioScience, Inc.
Maili Bergman, 310-883-1300
investorrelations@abraxisbio.com
or
Pondel Wilkinson Inc.
Rob Whetstone, 310-279-5963
investor@pondel.com

Copyright Business Wire 2009